These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
605 related articles for article (PubMed ID: 18535873)
1. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873 [TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358 [TBL] [Abstract][Full Text] [Related]
3. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Welin S; Stridsberg M; Cunningham J; Granberg D; Skogseid B; Oberg K; Eriksson B; Janson ET Neuroendocrinology; 2009; 89(3):302-7. PubMed ID: 19176944 [TBL] [Abstract][Full Text] [Related]
4. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194 [TBL] [Abstract][Full Text] [Related]
5. [The scintigraphy of somatostatin receptors in the carcinoid tumor]. Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324 [TBL] [Abstract][Full Text] [Related]
6. Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours. Rodrigues M; Gabriel M; Heute D; Putzer D; Griesmacher A; Virgolini I Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1796-802. PubMed ID: 18425512 [TBL] [Abstract][Full Text] [Related]
7. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography]. Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669 [TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings. Kuyumcu S; Adalet I; Sanli Y; Turkmen C; Ozkan ZG; Yilmazbayhan D Ann Nucl Med; 2012 Nov; 26(9):689-97. PubMed ID: 22802007 [TBL] [Abstract][Full Text] [Related]
10. Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Yellin A; Zwas ST; Rozenman J; Simansky DA; Goshen E Isr Med Assoc J; 2005 Nov; 7(11):712-6. PubMed ID: 16308994 [TBL] [Abstract][Full Text] [Related]
11. [Bronchial carcinoid tumor and scintigraphy of somatostatin receptors: detection of bone metastasis]. Banzo J; Abós MD; Prats E; García F; Freile E; Razola P; Escalera T Rev Esp Med Nucl; 2001 Oct; 20(6):431-8. PubMed ID: 11578577 [TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors. Stokkel MP; Rietbergen DD; Korse CM; Taal BG Nucl Med Commun; 2011 Aug; 32(8):731-7. PubMed ID: 21633314 [TBL] [Abstract][Full Text] [Related]
13. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129 [TBL] [Abstract][Full Text] [Related]
14. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis. Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104 [TBL] [Abstract][Full Text] [Related]
15. Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report. Kos-Kudła B; Zemczak A; Foltyn W; Marek B; Strzelczyk J; Telega A; Zajecki W; Legaszewski T; Jurecka-Lubieniecka B Endokrynol Pol; 2007; 58(2):123-9. PubMed ID: 17578828 [TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Kälkner KM; Janson ET; Nilsson S; Carlsson S; Oberg K; Westlin JE Cancer Res; 1995 Dec; 55(23 Suppl):5801s-5804s. PubMed ID: 7493349 [TBL] [Abstract][Full Text] [Related]
17. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Belhocine T; Foidart J; Rigo P; Najjar F; Thiry A; Quatresooz P; Hustinx R Nucl Med Commun; 2002 Aug; 23(8):727-34. PubMed ID: 12124477 [TBL] [Abstract][Full Text] [Related]
19. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors]. Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic imaging of carcinoid metastases to the abdomen and pelvis. Cwikła JB; Buscombe JR; Caplin ME; Watkinson AF; Walecki J; Gorczyca-Wiśniewska E; Hilson AJ Med Sci Monit; 2004 Jun; 10 Suppl 3():9-16. PubMed ID: 16538192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]